BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue, Suite 100

Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817


SEARCH JOBS

View Clinical Trials from BioPharm Insight





Collaborations

AVANIR Pharmaceuticals 





 Company News
Preclinical Data Presented At AACR Demonstrate Synergistic Anti-Tumor Effects Of Peregrine Pharmaceuticals, Inc. (PPHM)'s Phosphatidylserine (PS)-Targeting Antibodies With Immune Checkpoint Inhibitors In Models Of Melanoma And Breast Cancer 4/21/2015 8:04:09 AM
Data Presented At AACR Demonstrate Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab Induces Immune Activation In PD-L1 Negative NSCLC Tumors 4/20/2015 8:28:55 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Three Abstracts Accepted For Presentation At American Association for Cancer Research 2015 Annual Meeting 4/15/2015 4:02:59 PM
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Promising Bavituximab Phase I Data Published In The Peer-Reviewed Journal Cancer Medicine In Advanced Metastatic Breast Cancer 3/31/2015 11:02:49 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Reports Third Quarter Fiscal Year 2015 Financial Results And Recent Developments 3/13/2015 7:18:53 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 3/11/2015 7:31:52 AM
Peregrine Pharmaceuticals, Inc. (PPHM) To Report Third Quarter Fiscal 2015 Financial Results After Market On March 12, 2015 3/6/2015 7:33:48 AM
Peregrine Pharmaceuticals, Inc. (PPHM) To Present At The 27th Annual ROTH Conference 3/3/2015 8:23:59 AM
Newly Presented Data Shows That Peregrine Pharmaceuticals, Inc. (PPHM)' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity Of Immune Checkpoint Inhibitors PD-1 And CTLA-4 In Models Of Breast Cancer And Melanoma 2/9/2015 12:14:44 PM
Phase II Clinical Data Of Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Combination With Sorafenib Presented At American Society of Clinical Oncology Gastrointestinal Cancers Symposium 1/16/2015 10:33:57 AM
12345678910...